Yesterday, after market closure, AstraZeneca today announced its decision of further investing $ 90 million over the next 5 years in India.

This investment commitment will span across AstraZeneca’s diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of care of non-communicable diseases in India.

The company recently announced expansion of its Global Technology Centre (GTC) in Chennai, now employing more than 2000 employees. GTC is AstraZeneca’s first, insourced IT facility.

AstraZeneca’s manufacturing facility in Bengaluru has a sophisticated production facility designed to meet the most stringent international standards, conforming to World Health Organisation cGMP (current Good Manufacturing Practices) norms.

 AstraZeneca also has a sizeable clinical operation and is expanding its Global medicines development unit that focusses on patient safety and regulatory science in India.

The stock price rose over 5% to Rs.1045.50 and it continues to remain firmly in the green today morning.